Global Partners L.P. (GLP)
NYSE NYSE Primary 
Oil's 31% Q2 Selloff Opens the Door to 3 Strong Buy Stocks
Lower crude prices have reset energy-sector expectations, making GLP, NESR and IMO buy candidates for investors seeking oil-linked opportunities.
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.
Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk's oral Wegovy launch sets a new benchmark, highlighting peptide-based oral GLP-1 drugs' commercial potential and raising the value of VKTX's oral program. VKTX's injectable VK2735 faces intensified competition after Eli Lilly's Retatrutide Phase III results, which establish a higher efficacy standard (>24%).
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.
Citi says Wegovy pill outpacing rivals as oral GLP-1 race heats up
Citi has said Novo Nordisk's (NYSE:NVO) Wegovy pill is outpacing its rivals in the United States, even as competition in the oral weight-loss market intensifies. The broker's prescription tracker showed the oral version of Wegovy reached around 152,000 US prescriptions in its 24th week of launch, in the week ending 19 June.
Bank sees structural strength in GLP-1 market as obesity drives demand
UBS says the market for GLP-1 obesity and diabetes drugs remains structurally strong, with obesity the key driver of growth, in a note backing its positive stance on the sector's key suppliers. The bank, drawing on a call with its US biotech analyst Michael Yee, put the global market at around $130 billion to $135 billion by 2030.
Global Partners (GLP) Surges 6.9%: Is This an Indication of Further Gains?
Global Partners (GLP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
The GLP-1 revolution is quietly continuing even as investor interest has moved on to more timely topics. One of the best ways to access the fast-growing weight loss drug space is via makers like Novo Nordisk NYSE: NVO or Eli Lilly NYSE: LLY, the leading companies responsible for developing and manufacturing products like Ozempic and Zepbound.
Is Global Partners (GLP) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Ozempic Linked To Lower Risk Of Violence In New Study
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, said it is important to continue studying the impact of GLP-1 medications on users' behavior and public safety as the medications become more widespread.
